| 22.14 0.56 (2.6%) | 09-22 10:05 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 27.39 | 1-year : | 29.03 |
| Resists | First : | 23.45 | Second : | 24.86 |
| Pivot price | 22.41 |
|||
| Supports | First : | 21.18 | Second : | 17.62 |
| MAs | MA(5) : | 21.95 |
MA(20) : | 22.78 |
| MA(100) : | 19.35  |
MA(250) : | 23.63 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 22.7 |
D(3) : | 26.5 |
| RSI | RSI(14): 43.6 |
|||
| 52-week | High : | 34.29 | Low : | 13.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VRDN ] has closed above bottom band by 14.4%. Bollinger Bands are 38.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.21 - 22.32 | 22.32 - 22.41 |
| Low: | 21.54 - 21.66 | 21.66 - 21.77 |
| Close: | 21.81 - 22.01 | 22.01 - 22.17 |
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Sat, 19 Sep 2026
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
Thu, 17 Sep 2026
Viridian Therapeutics: Two Products, One Commercial Buildout (NASDAQ:VRDN) - Seeking Alpha
Wed, 02 Sep 2026
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Thu, 20 Aug 2026
Viridian Therapeutics (VRDN) legal chief sells 14,212 shares - Stock Titan
Sun, 09 Aug 2026
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Thu, 06 Aug 2026
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 1.0079e+008 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 18,920 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.0473e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -44 % |
| Return on Assets (ttm) | 460.5 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | 7.113e+007 % |
| Gross Profit (p.s.) | 290.31 |
| Sales Per Share | -68.48 |
| EBITDA (p.s.) | -2.64115e+008 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -333 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.32 |
| Price to Cash Flow | 4.21 |
| Dividend | 0 |
| Forward Dividend | 1.903e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|